Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Ebola Drug Gets FDA Fast Track Status

By Reuters Staff | on September 22, 2015 | 0 Comment
Latest News
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

Mapp Biopharmaceutical Inc. said on Sept. 17 that the U.S. Food and Drug Administration (FDA) granted fast track status to its Ebola drug ZMapp. The FDA grants the status to drugs intended to treat serious conditions that have few or no treatment options and expedites the review of such drugs.

You Might Also Like
  • Takeda’s Zika Vaccine Gets U.S. FDA’s ‘Fast Track’ Status
  • CDC Ebola Expert Tim Uyeki, MD, MPH, Offers Ebola Management and Safety Information
  • FDA Seeks Suspension of 4,402 Illegal Prescription Drug Websites

ZMapp, which also has an orphan drug status from the regulator, was first tested on humans during the Ebola virus outbreak in West Africa in 2014, but was not subjected to controlled trial to determine its potential. The drug was given on an emergency basis initially to sick health workers evacuated from the region.

The Ebola epidemic is the largest in history, affecting multiple countries in West Africa, according to the Centers for Disease Control and Prevention. Cases were reported in Liberia, Nigeria, Mali, Senegal, and the disease has killed more than 11,000 people since 2013.

Topics: CDCCenters for Disease Control and PreventionEbolaFDA

Related

  • Diabetes, Lung, and Heart Disease Common in U.S. COVID-19 Patient

    April 1, 2020 - 0 Comment
  • COVID-19 for the Emergency Physicians: What You Need to Know

    March 10, 2020 - 5 Comments
  • FDA Drug Shortage Task Force Releases Long-Awaited Report

    December 20, 2019 - 0 Comment

Current Issue

ACEP Now: June 2025 (Digital)

Read More

No Responses to “Ebola Drug Gets FDA Fast Track Status”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*


Current Issue

ACEP Now: June 2025 (Digital)

Read More

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603